InspireMD touts results of next-gen stroke prevention stent study

InspireMD (NYSE:NSPR) has released the results of a meta-analysis of four clinical studies involving dual-layered (DLS) and mesh-covered stents, including the company’s MicroNet-covered stent, the CGuard embolic prevention system. The analysis concluded that carotid artery disease patients treated with mesh-covered stents experienced a 30-day minor stroke rate of 1.25%, lower than the 30-day minor stroke rates reported in other widely cited studies, such as CREST and ACT 1, for patients treated with both carotid endarterectomy and with those treated with conventional carotid stents. CREST and ACT 1 also involved lower-risk patient populations as compared to the four studies included in the meta-analysis, which included a higher percentage of high-risk and elderly patients, according to the company. The analysis was published in JACC: Cardiovascular Interventions. Get the full story on our sister site, Medical Design & Outsourcing. The post InspireMD touts results of next-gen stroke prevention stent study appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Blog Cardiovascular Research & Development Stents InspireMD Terumo Source Type: news